Two years safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with HBV-induced cirrhosis

被引：0
|
作者：
Strasser, S. I.
Gane, E. J.
Weilert, F.
Sievert, W.
George, J.
Crawford, D.
Ngu, M. C.
Heathcote, E. J.
Marcellin, P.
Sorbel, J.
Rousseau, F.
机构：
[1] Royal Prince Alfred Hosp, AW Morrow GE & Liver Ctr, Sydney, NSW, Australia
[2] Middlemore Hosp, Dept Gastroenterol, Manukau City, New Zealand
[3] Waikato Hosp, Hamilton, New Zealand
[4] Monash Med Ctr, Clayton, Vic, Australia
[5] Westmead Hosp, Storr Liver Unit, Univ Sydney, Westmead, NSW, Australia
[6] Princess Alexandra Hosp, Dept Gastroenterol & Hepatol, Woolloongabba, Qld, Australia
[7] Concord Repatriat Gen Hosp, Dept Gastroenterol, Concord, NSW, Australia
[8] Univ Toronto, Dept Gastroenterol, Toronto, ON M5S 1A1, Canada
[9] Univ Paris, Clichy, France
[10] Gilead Sci Inc, Durham, NC USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2009年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A309 / A309
页数：1
相关论文
共 50 条
  • [41] RENAL SAFETY AND ANTIVIRAL EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) MONOTHERAPY IN NUCLEOS(T)IDE ANALOGUE REFRACTORY PATIENTS WITH HEPATITIS B VIRUS (HBV) MONO-INFECTION
    van Boemmel, F.
    De Man, R. A.
    Ferenci, P.
    Reijnders, J. G.
    Bronowicki, J. -P.
    Wedemeyer, H.
    Brodzinski, A.
    Fueloep, B.
    Deterding, K.
    Erhardt, A.
    Hueppe, D.
    Bourliere, M.
    Sarrazin, C.
    Trojan, J.
    Buggisch, P. B.
    Petersen, J.
    Spengler, U.
    Pariente, A.
    Schuchmann, M.
    Wasmuth, H.
    Stein, K.
    Rutter, K.
    Feucht, H. -H.
    Wiedenmann, B.
    Berg, T.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S398 - S398
  • [42] Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use
    Gane, E.
    Seto, W-K.
    Janssen, H.
    Caruntu, F. A.
    Kim, H. J.
    Abdurakhmanov, D.
    Nishiguchi, S.
    Andrzej, H.
    Bae, H.
    Mo, S.
    Suri, V.
    Gaggar, A.
    Flaherty, J. F.
    Kao, J-H.
    Brunetto, M.
    Ferret, M. B.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S87 - S87
  • [43] A EUROPEAN FIELD STUDY OF THE EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) AS MONOTHERAPY IN PATIENTS WITH PRIOR FAILURE TO OTHER NUCLEOSIDE/NUCLEOTIDE ANALOGUES
    van Boemmel, F.
    Zoutendijk, R.
    de Man, R.
    Bronowiki, J. -P.
    Rutter, K.
    Ferenci, P.
    Janssen, H.
    Fueloep, B.
    Brodzinski, A.
    Wiegand, J.
    Wedemeyer, H.
    Deterding, K.
    Erhardt, A.
    Hueppe, D.
    Bourliere, M.
    Sarrazin, C.
    Trojan, J.
    Buggisch, P.
    Petersen, J.
    Spengler, U.
    Kamp, A.
    Mauss, S.
    Schuchmann, M.
    van Nieuwkerk, K.
    Gerlach, T.
    Moradpour, D.
    Schweinberger, A.
    Wasmuth, H.
    Berg, T.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S216 - S216
  • [44] EFFICACY AND SAFETY OF LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR (TDF) IN PATIENTS WITH HBV-RELATED CIRRHOSIS
    Fasano, M.
    Ciarallo, M.
    Giammario, A.
    Caccianotti, B.
    Angarano, G.
    Santantonio, T.
    DIGESTIVE AND LIVER DISEASE, 2014, 46 : E140 - E140
  • [45] Factors associated with regression of cirrhosis in patients with chronic hepatitis B (CHB) infection treated with tenofovir disoproxil fumarate (TDF)
    Gane, Ed
    Afdhal, Nezam
    Buti, Maria
    Elsome, Amanda M.
    Flaherty, John F.
    Martins, Eduardo
    Bekele, Neby
    Bornstein, Jeffrey D.
    Marcellin, Patrick
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 164 - 164
  • [46] Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/TDF, and Entecavir in Patients with Decompensated Chronic Hepatitis B Liver Disease
    Liaw, Yun-Fan
    Sheen, I-Shyan
    Lee, Chuan-Mo
    Akarca, Ulus Salih
    Papatheodoridis, George V.
    Wong, Florence Suet-Hing
    Chang, Ting-Tsung
    Horban, Andrzej
    Wang, Chia
    Kwan, Peter
    Buti, Maria
    Prieto, Martin
    Berg, Thomas
    Kitrinos, Kathryn
    Peschell, Ken
    Mondou, Elsa
    Frederick, David
    Rousseau, Franck
    Schiff, Eugene R.
    HEPATOLOGY, 2011, 53 (01) : 62 - 72
  • [47] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study
    Stroffolini, Giacomo
    Dodaro, Valentina
    De Nicolo, Amedeo
    Cusato, Jessica
    Di Perri, Giovanni
    D'Avolio, Antonio
    Boglione, Lucio
    JOURNAL OF CLINICAL VIROLOGY PLUS, 2024, 4 (01):
  • [48] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE FUMARATE VERSUS TENOFOVIR DISOPROXIL FUMARATE IN PREVENTING MOTHER- TO- CHILD TRANSMISSION OF HBV: A PROSPECTIVE COHORT STUDY
    Yang, Liuqing
    Zhang, Li
    Liu, Yingxia
    HEPATOLOGY, 2023, 78 : S459 - S460
  • [49] SAFETY AND EFFICACY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE THERAPY IN LAMIVUDINE EXPERIENCED PATIENTS
    Manns, M.
    Jeffers, L.
    Dalekos, G.
    Berg, T.
    Trepo, C.
    Roberts, S.
    Prieto, M.
    Rizzetto, M.
    Marcellin, P.
    Heathcote, E. J.
    Sorbel, J.
    Anderson, J.
    Mondou, E.
    Rousseau, F.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S335 - S336
  • [50] Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate Therapy in Lamivudine Experienced Patients
    Manns, Michael P.
    Jeffers, Lennox
    Delakos, Georgios N.
    Berg, Thomas
    Trepo, Christian
    Roberts, Stuart K.
    Prieto, Martin
    Rizzetto, Mario
    Marcellin, Patrick
    Heathcote, Jenny
    Sorbel, Jeff
    Anderson, Jane
    Mondou, Elsa
    Rousseau, Franck
    GASTROENTEROLOGY, 2009, 136 (05) : A799 - A799
12345